Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Body composition and paclitaxel-albumin pharmacokinetics/toxicity in malignant tumors (Northern China)
ChiCTR2000040918Phase 4Recruiting
- Sponsor
- Ordos Central Hospital
- Start
- Jan 2021
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nab-paclitaxel in cancer and Nonhematologic neoplasms, sponsored by Ordos Central Hospital. Primary endpoints: bioelectrical impedance, muscle area of lumbar vertebra (L3) and 4 more. Started Jan 2021; status: recruiting.
02
Drugs
nab-paclitaxel
03
Conditions
cancerNonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2000040918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040918.